Enhanced Anti-Inflammatory Peptide Compositions and Delivery Systems

The present inventive concept relates to improved anti-inflammatory peptide compositions and delivery systems, enhancing the bioavailability, solubility, and retention time of the peptides, thereby increasing their therapeutic efficacy.

The original patent disclosed anti-inflammatory peptides and compositions, but these peptides may have limitations in terms of bioavailability, solubility, and retention time, which can reduce their therapeutic efficacy. The present inventive concept addresses these limitations by introducing novel compositions and delivery systems that enhance the peptides' properties.

The inventive concept comprises a system for treating inflammatory diseases, which includes a composition of SEQ ID NO: 1 peptide and a carrier molecule that enhances the bioavailability of the peptide by at least 20%. Additionally, the concept involves conjugating the peptide with a lipophilic moiety to increase its solubility in lipids, and formulating the peptide with a mucoadhesive polymer to enhance its retention time at the site of inflammation. Furthermore, the concept includes a peptide-based composition that combines SEQ ID NO: 1 peptide with a second peptide having synergistic anti-inflammatory activity, and a method for reducing the dosage of SEQ ID NO: 1 peptide required for treating inflammatory diseases by co-administering it with a cyclooxygenase-2 inhibitor.

The novelty of the present inventive concept lies in the introduction of carrier molecules, lipophilic moieties, and mucoadhesive polymers that enhance the bioavailability, solubility, and retention time of the anti-inflammatory peptides. The inventive step resides in the specific combinations and formulations of these components, which provide a significant improvement over the original patent.

Alternative embodiments of the inventive concept may include different types of carrier molecules, lipophilic moieties, and mucoadhesive polymers. Additionally, the peptides could be formulated with other excipients or additives to further enhance their properties. The concept could also be adapted for use in different routes of administration, such as topical or inhalation.

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of treatments for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease. The enhanced bioavailability, solubility, and retention time of the peptides could lead to more effective and efficient treatments, with potential market opportunities in the billions of dollars.